YahooAugust 12, 2026 at 6:50 AM NY23 days ago

BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with successful completion of enrollment in the PREVENT clinical trial evaluating Phasix™ Mesh for the prevention of incisional hernias.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Yahoo

Read at Source

Companies in This Story

BDXBecton Dickinson and Co185.25− 1.26%

Companies in This Story

Related Stories